Veridex of Raritan, NJ, has received US Patent No. 8,183,353, "Breast cancer prognostics." A method is claimed for assessing the likelihood of a recurrence or metastasis of breast cancer in a patient diagnosed with or treated for breast cancer. The method involves the analysis of a gene expression profile that includes up to 56 genes. Arrays to capture and indicate the presence, absence, or degree of gene expression are also described as are kits that include reagents for conducting the gene expression analysis.